Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07205887 · ClinicalTrials.gov registry record · Phase 2
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
A Phase 2 study of Neovascular Age-Related Macular Degeneration (NVAMD) and Branch Retinal Vein Occlusion (BRVO), sponsored by EyeBiotech.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT07205887 is a Phase 2 study of Neovascular Age-Related Macular Degeneration (NVAMD) and Branch Retinal Vein Occlusion (BRVO) that is actively recruiting participants, run by EyeBiotech. The registered enrollment target is 160 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT07205887, a Phase 2 study of Neovascular Age-Related Macular Degeneration (NVAMD) and Branch Retinal Vein Occlusion (BRVO), is actively recruiting participants, sponsored by EyeBiotech.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
EYE-RES-104 is a randomized, dose-masked study of intravitreal EYE103 in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO). The study will consist of 4 patient cohorts, with participants in each cohort randomized (1:1) to either a low dose of EYE103 via IVT or a high dose of EYE103 via IVT. 40 participants will be enrolled in each cohort. Enrollment timing for each cohort will be sequenced into specific arms of the study at the Sponsor's discretion. All participants in the study will receive a total of 3 injections of EYE103 into the study eye, spaced at 4 weeks apart. All participants will return at designated time points following each injection for safety and efficacy assessments. The Week 12 Visit will serve as the end of study visit for all participants.
Conditions Studied
Interventions
- DRUG EYE103
- DRUG Aflibercept 2.0 mg
Study Locations (20)
California
- Glendale, California - Glendale
- Glendale, CA - Glendale
- Modesto, California - Modesto
- Mountain View, California - Mountain View
- Sacramento, CA - Sacramento
- Sactamento, California - Sacramento
- Sacramento, California - Sacramento
- Santa Ana, California - Santa Ana
Arizona
- Scottsdale, Arizona - Scottsdale
- Scottsdale, AZ - Scottsdale
Florida
- Fort Lauderdale, Florida - Fort Lauderdale
- Fort Lauderdale, FL - Fort Lauderdale
Illinois
- Lemont, Illinois - Lemont
- Lemont, IL - Lemont
Maryland
- Hagerstown, Maryland - Hagerstown
- Hagerstown, MD - Hagerstown
Mississippi
- Madison, Mississippi - Madison
- Madison, MS - Madison
New Jersey
- Bloomfield, New Jersey - Bloomfield
- Bloomfield, NJ - Bloomfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-09-12 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07205887
The ClinicalTrials.gov registry entry for NCT07205887 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EyeBiotech, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neovascular Age-Related Macular Degeneration (NVAMD) appearing as the primary indexed condition, and to 2 interventions - of which EYE103 is the first listed.
NCT07205887 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT07205887 about?
NCT07205887 is a clinical study titled "A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO". EYE-RES-104 is a randomized, dose-masked study of intravitreal EYE103 in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO). The study will consist of 4 patient cohorts, with participants in each cohort randomized (...
What is the current status of trial NCT07205887?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2025-09-12. Estimated completion is 2028-06-30.
What conditions does trial NCT07205887 study?
This clinical trial studies the following conditions: Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO).
What interventions are being tested in trial NCT07205887?
The interventions under investigation include: EYE103 (DRUG), Aflibercept 2.0 mg (DRUG).
Who is sponsoring clinical trial NCT07205887?
This trial is sponsored by EyeBiotech, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07205887 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-Related Macular Degeneration (NVAMD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Neovascular Age-Related Macular Degeneration (NVAMD)
All registered trials for this condition
Branch Retinal Vein Occlusion (BRVO)
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.